Did Grobbelaar et al.'s research showing spike protein S1 sub-unit induces fibrin(ogen) resistant to fibrinolysis then implicate the mRNA technology based gene injection in microclots? Yes! 100%
by Paul Alexander
the presence of spike protein in circulation may contribute to hypercoagulation in COVID patients & may cause substantial impairment of fibrinolysis that may result in large microclots
Studied ‘the effect of isolated SARS-CoV-2 spike protein S1 subunit as potential inflammagen sui generis. Using scanning electron and fluorescence microscopy as well as mass spectrometry, we investigate the potential of this inflammagen to interact with platelets and fibrin(ogen) directly to cause blood hypercoagulation. Using platelet-poor plasma (PPP), we show that spike protein may interfere with blood flow.
Mass spectrometry also showed that when spike protein S1 is added to healthy PPP, it results in structural changes to β and γ fibrin(ogen), complement 3, and prothrombin. These proteins were substantially resistant to trypsinization, in the presence of spike protein S1…
the presence of spike protein in circulation may contribute to the hypercoagulation in COVID-19 positive patients and may cause substantial impairment of fibrinolysis.’ We can extrapolate this effect for virus and vaccine spike protein…
Such lytic impairment may result in the persistent large microclots we have noted here and previously in plasma samples of COVID-19 patients. This observation may have important clinical relevance in the treatment of hypercoagulability in COVID patients’ as well as those in receipt of the mRNA technology gene injection.’